SUSAN ZEMITIS: Open Payments
NPI 1093483505 · ALEXANDRIA, VA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,831 in 125 payments from 22 companies in 2025. Trend: 2023 $0 · 2024 $1,607 · 2025 $2,831
Food & beverage: $2,831
| Company | Payments | Amount |
|---|---|---|
| Gilead Sciences, Inc. | 16 | $385 |
| ABBVIE INC. | 21 | $367 |
| Ardelyx, Inc. | 19 | $345 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 14 | $312 |
| PFIZER INC. | 8 | $168 |
| Ipsen Biopharmaceuticals, Inc | 7 | $152 |
| Novo Nordisk Inc | 2 | $141 |
| Takeda Pharmaceuticals U.S.A., Inc. | 6 | $135 |
| Ethicon US, LLC | 1 | $130 |
| Lilly USA, LLC | 4 | $100 |
Products named: IBSRELA, XIFAXAN, RINVOQ, IQIRVO, Wegovy, ENTYVIO, LINX REFLUX MANAGEMENT SYSTEM, DUPIXENT.
Industry payments across VA — which companies pay providers there.
